ReviewCells2020
Taming the Autophagy as a Strategy for Treating COVID-19.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 61 citations in OpenAlex.
- Autophagy, telomerase, and endothelial dysfunction in COVID-19-induced cardiac injury: an evidence-graded genetic and epigenetic synthesis.Frontiers in cardiovascular medicine · 2026Review
- Autophagy in emerging and highly concerned severe zoonotic infectious diseases.Frontiers in immunology · 2026Review
- ATG10S promotes IFNL1 expression and autophagic degradation of multiple viral proteins mediated by IFNL1.Autophagy · 2024Article
- Understanding the molecular regulatory mechanisms of autophagy in lung disease pathogenesis.Frontiers in immunology · 2024Review
- Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases.Frontiers in molecular biosciences · 2024Article
- New insights on the potential effect of progesterone in Covid-19: Anti-inflammatory and immunosuppressive effects.Immunity, inflammation and disease · 2023Review
- Autophagy in Inflammatory Response against SARS-CoV-2.International journal of molecular sciences · 2023Review
- Neutrophil autophagy and NETosis in COVID-19: perspectives.Autophagy · 2023Review
- Host mitochondria: more than an organelle in SARS-CoV-2 infection.Frontiers in cellular and infection microbiology · 2023Review
- Modeling structure-activity relationships with machine learning to identify GSK3-targeted small molecules as potential COVID-19 therapeutics.Frontiers in endocrinology · 2023Article
- Tumor Treating Fields (TTFields) demonstrate antiviral functionsFrontiers in microbiology · 2023Article
- Article
- Review
- Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.Clinical immunology (Orlando, Fla.) · 2022Review
- Autophagy in severe acute respiratory syndrome coronavirus 2 infection.Current opinion in physiology · 2022Review
- Challenges in the Detection of SARS-CoV-2: Evolution of the Lateral Flow Immunoassay as a Valuable Tool for Viral Diagnosis.Biosensors · 2022Review
- Post-COVID-19 Parkinsonism and Parkinson's Disease Pathogenesis: The Exosomal Cargo Hypothesis.International journal of molecular sciences · 2022Review
- Review
- The role of electrochemical biosensors in SARS-CoV-2 detection: a bibliometrics-based analysis and review.RSC advances · 2022Review
- Epigenetic regulation of autophagy in coronavirus disease 2019 (COVID-19).Biochemistry and biophysics reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Currently, an efficient treatment for COVID-19 is still unavailable, and people are continuing to die from complications associated with SARS-CoV-2 infection. Thus, the development of new therapeutic approaches is urgently needed, and one alternative is to target the mechanisms of autophagy. Due to its multifaceted role in physiological processes, many questions remain unanswered about the possible advantages of inhibiting or activating autophagy. Based on a search of the literature in this field, a novel analysis has been made to highlight the relation between the mechanisms of autophagy in antiviral and inflammatory activity in contrast with those of the pathogenesis of COVID-19. The present analysis reveals a remarkable coincidence between the uncontrolled inflammation triggered by SARS-CoV-2 and autophagy defects. Particularly, there is conclusive evidence about the substantial contribution of two concomitant factors to the development of severe COVID-19: a delayed or absent type I and III interferon (IFN-I and IFN-III) response together with robust cytokine and chemokine production. In addition, a negative interplay exists between autophagy and an IFN-I response. According to previous studies, the clinical decision to inhibit or activate autophagy should depend on the underlying context of the pathological timeline of COVID-19. Several treatment options are herein discussed as a guide for future research on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.